Current evidence for histone deacetylase inhibitors in pancreatic cancer

作     者：Ioannis Koutsounas Constantinos Giaginis Efstratios Patsouris Stamatios Theocharis 

作者机构：First Department of PathologyMedical SchoolNational and Kapodistrian University of AthensGR-11527 AthensGreece Department of Food Science and NutritionUniversity of the AegeanGR-81400 LemnosGreece 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第6期

页      面：813-828页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Pancreatic cancer Histone deacetylases Histone deacetylase inhibitors Experimental studies 

摘      要：Pancreatic cancer is one of the most aggressive human cancers,with more than 200 000 deaths worldwide every *** recent efforts,conventional treatment approaches,such as surgery and classic chemotherapy,have only slightly improved patient *** effective and well-tolerated therapies are required to reverse the current poor prognosis of this type of *** new agents,histone deacetylase inhibitors (HDACIs) are now being *** have multiple biological effects related to acetylation of histones and many non-histone proteins that are involved in regulation of gene expression,apoptosis,cell cycle progression and *** induce cell cycle arrest and can activate the extrinsic and intrinsic pathways of apoptosis in different cancer cell *** the present review,the main mechanisms by which HDACIs act in pancreatic cancer cells in vitro,as well as their antiproliferative effects in animal models are *** constitute a promising treatment for pancreatic cancer with encouraging anti-tumor ef-fects,at well-tolerated doses.